Literature DB >> 8639063

The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.

.   

Abstract

OBJECTIVES: To test the utility of a new, easy to administer instrument for assessing activities of daily living in patients with amyotrophic lateral sclerosis (ALS), to validate its accuracy, and to assess its ability to record disease progression in patients with ALS against other functional scales, quantitative isometric muscle testing, and global assessment scales.
DESIGN: Serial assessments of patients who presented to four ALS treatment centers in two multicenter studies. PATIENTS: Study 1 (cross-sectional) evaluated 75 consecutive patients who presented to four ALS treatment centers during a 2-month period. Study 2 (longitudinal) evaluated the progression of 53 patients who were enrolled in a multicenter, phase I-II clinical trial of recombinant human ciliary neurotrophic factor for treatment of ALS. OUTCOME MEASURES: The ALS Functional Rating Scale (ALSFRS) was compared with quantitative myometry and with other measures of daily function in patients with ALS both cross-sectionally and longitudinally.
RESULTS: The first study of 75 patients evaluated the internal consistency, the test-retest reliability, and the construct validity of the ALSFRS. Internal consistency and test-retest reliability were high. Patient self-rating of upper- and lower-extremity-dependent tasks were highly correlated with measures of upper- and lower-extremity strength, respectively. Thus, the ALSFRS has good construct validity. In the second study, ALSFRS scores declined in tandem with deterioration in motor and pulmonary function, indicating its sensitivity to change.
CONCLUSIONS: The ALSFRS is a useful instrument for evaluation of functional status and functional change in patients with ALS. Its results are in close agreement with objective measures of muscle strength and pulmonary function. The ALSFRS may be used as a screening measure for entry into clinical trials, as a surrogate measure of function in situations in which muscle strength cannot be measured directly, or as an adjunct to myometry.

Entities:  

Mesh:

Year:  1996        PMID: 8639063

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  87 in total

1.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

2.  Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40.

Authors:  C Jenkinson; R Fitzpatrick; C Brennan; M Bromberg; M Swash
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

3.  Assessing individual quality of life in amyotrophic lateral sclerosis.

Authors:  S Clarke; A Hickey; C O'Boyle; O Hardiman
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

Review 4.  Advances in clinical trials for amyotrophic lateral sclerosis.

Authors:  Paul H Gordon
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

Review 5.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

6.  Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS).

Authors:  Johannes Brettschneider; Helga Mogel; Vera Lehmensiek; Tino Ahlert; Sigurd Süssmuth; Albert C Ludolph; Hayrettin Tumani
Journal:  Neurochem Res       Date:  2008-05-15       Impact factor: 3.996

7.  Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes.

Authors:  Jue Wang; Sheng Luo
Journal:  Stat Med       Date:  2017-06-01       Impact factor: 2.373

8.  A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Keisuke Suzuki; Haruhiko Banno; Noriaki Suga; Tomoo Mano; Amane Araki; Yasuhiro Hijikata; Christopher Grunseich; Angela Kokkinis; Akihiro Hirakawa; Hirohisa Watanabe; Masahiko Yamamoto; Kenneth H Fischbeck; Gen Sobue
Journal:  Neuromuscul Disord       Date:  2015-03-20       Impact factor: 4.296

9.  Risk of sporadic amyotrophic lateral sclerosis associated with seropositivity for herpesviruses and echovirus-7.

Authors:  C Cermelli; M Vinceti; F Beretti; V Pietrini; G Nacci; P Pietrosemoli; A Bartoletti; D Guidetti; P Sola; M Bergomi; G Vivoli; M Portolani
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

10.  Effects of noninvasive ventilation on sleep outcomes in amyotrophic lateral sclerosis.

Authors:  Hans D Katzberg; Adam Selegiman; Lee Guion; Nancy Yuan; Sungho C Cho; Jonathan S Katz; Robert G Miller; Yuen T So
Journal:  J Clin Sleep Med       Date:  2013-04-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.